The Liver Meeting 2020-Hepatobiliary Neoplasia SIG & Liver Transplantation and Surgery SIG - Part 2 Hot Topics in the Pathogenesis and Treatment of Liver Cancer (HCC and iCCA)

Hepatobiliary Neoplasia SIG & Liver Transplantation and Surgery SIG - Part 2 Hot Topics in the Pathogenesis and Treatment of Liver Cancer (HCC and iCCA)

Back to course

Video Transcription

Video Summary

The video discusses hot topics in the pathogenesis and treatment of liver cancer, focusing on hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Key speakers present on trial design, immunotherapy, precision oncology, and management strategies. Promising approaches include combining immune checkpoint inhibitors with anti-angiogenic agents for improved outcomes. Examples such as the Iembraaf 150 trial show potential benefits in this approach. Therapeutic targets in ICCA and HCC include FGFR2 fusions, BRAF V600E mutation, IDH1 mutations, and MSI-high or mismatch repair deficiency. Treatments like FGFR2 inhibitors, BRAF/MEK inhibitors, IDH1 inhibitors, and PD-1 inhibitors have shown efficacy in targeting these mutations. Tumor sequencing is crucial in guiding treatment decisions based on actionable mutations, with molecular tumor boards playing a significant role. Challenges in access to tumor samples, efficacy of targeted therapies, and risks of off-label drug use are discussed. The importance of considering safety, financial implications, and workload when using off-label therapies is highlighted. Overall, tumor sequencing and molecular tumor board review are essential in optimizing treatment strategies for advanced liver cancers by identifying actionable mutations and guiding personalized therapy decisions.

Keywords

Liver cancer

Hepatocellular carcinoma

Intrahepatic cholangiocarcinoma

Trial design

Immunotherapy

Precision oncology

Management strategies

Immune checkpoint inhibitors

Anti-angiogenic agents

FGFR2 fusions

BRAF V600E mutation

Tumor sequencing